Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $33 | $19 | $25 | $21 |
| Short-Term Investments | $0 | $0 | $0 | $9 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $0 | $0 | $1 |
| Total Curr. Assets | $34 | $20 | $25 | $31 |
| Property Plant & Equip (Net) | $0 | $0 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $0 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $35 | $20 | $26 | $31 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $10 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $3 | $9 | $4 | $2 |
| Total Curr. Liab. | $3 | $19 | $4 | $2 |
| LT Debt | $0 | $0 | $12 | $10 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | -$0 | -$0 |
| Total NC Liab. | $0 | $0 | $12 | $10 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $3 | $19 | $16 | $12 |
| Equity | – | – | – | – |
| Pref Stock | $32 | $0 | $0 | $0 |
| Common Stock | $116 | $93 | $96 | $78 |
| Retained Earnings | -$131 | -$106 | -$105 | -$74 |
| AOCI | -$4 | -$3 | -$4 | $17 |
| Other Equity | $21 | $18 | $23 | $0 |
| Total Equity | $33 | $2 | $11 | $20 |
| Supplemental Information | – | – | – | – |
| Minority Interest | -$2 | -$1 | -$1 | -$1 |
| Total Liab. & Tot. Equity | $35 | $20 | $26 | $31 |
| Net Debt | -$33 | -$9 | -$13 | -$11 |